on Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Projects Significant Growth for 2025 and 2026
Viromed Medical AG anticipates substantial revenue growth in the coming years, as outlined in its recent forecast. The company predicts an increase in revenue from EUR 1.37 million in 2024 to between EUR 8 million and EUR 10 million by 2025. A significant surge is expected in 2026, with revenues projected to reach approximately EUR 80 million. This growth is aligned with existing partnerships and distribution agreements.
The financial outlook for 2025 is largely supported by operations of the newly acquired Pharmedix GmbH. Viromed anticipates new products like ViroCAP® and PulmoPlas® will further drive growth in 2026. Despite a low revenue in 2024 due to the end of cooperation with terraplasma medical GmbH, 2025 has already seen revenue more than double compared to the previous year's figures.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Viromed Medical AG news